Wellington Management Group LLP Purchases 25,932 Shares of Aquestive Therapeutics, Inc. $AQST

Wellington Management Group LLP increased its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 14.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 205,544 shares of the company’s stock after acquiring an additional 25,932 shares during the period. Wellington Management Group LLP owned about 0.21% of Aquestive Therapeutics worth $596,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Summit Wealth & Retirement Planning Inc. bought a new stake in shares of Aquestive Therapeutics in the first quarter worth $29,000. Victory Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics in the first quarter worth $31,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Aquestive Therapeutics in the first quarter worth $33,000. Two Sigma Advisers LP bought a new stake in shares of Aquestive Therapeutics in the fourth quarter worth $57,000. Finally, Virtu Financial LLC bought a new stake in shares of Aquestive Therapeutics in the first quarter worth $58,000. Institutional investors own 32.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Oppenheimer assumed coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They issued an “outperform” rating and a $7.00 price objective for the company. Zacks Research upgraded Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 13th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.14.

Aquestive Therapeutics Stock Down 1.6%

NASDAQ AQST opened at $3.77 on Tuesday. The firm has a market cap of $375.94 million, a price-to-earnings ratio of -5.39 and a beta of 1.82. The business has a 50-day moving average price of $3.87 and a 200-day moving average price of $3.21. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.